NL-OMON36711已完成不适用
Randomised, double-blind, placebo-controlled single ascending dose study investigating the safety, tolerability, pharmacokinetic and pharmacodynamic properties of the research medication in healthy young and elderly men, and open-label three-period crossover food interaction study of the research medication in healthy elderly men - 13065A
undbeck0 个研究点目标入组 171 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 171
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy Male
排除标准
- •Clinical significant abnormalities at medical research
研究者
相似试验
已完成
不适用
Randomized, double-blind, placebo-controlled single ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and food-effects of YTX-7739, a novel oral inhibitor of Stearoyl-CoA-desaturases, in healthy volunteersParkinson's diseaseNL-OMON49863Yumanity Therapeutics56
已完成
不适用
Randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects.supraventricular tachycardiaAtrial fibrillationNL-OMON46496Acesion Pharma ApS48
已完成
不适用
SAD and food-effect study of YTX-7739Parkinson's diseaseNL-OMON21001Yumanity Therapeutics48
进行中（未招募）
不适用
Prospective clinical study, where patients are receiving or the study drug or an inactive drug called placebo wihtout knowing which of the two drugs is taken, even the Investigator is aware of the therapy taken by the patients. Patients are assigned to a specific treatment according to a randomization list. The study is performed to assess the effects and tolerability of K(D)PT in ulcerative colitis.mild to moderate ulcerative colitisMedDRA version: 14.1Level: SOCClassification code 10017947Term: Gastrointestinal disordersSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-002462-20-ITDR. AUGUST WOLFF GMBH & CO. KG160
进行中（未招募）
不适用
Clinical trial to evaluate the efficacy and safety of K(D)PT in patients with mild to moderate ulcerative colitisEUCTR2011-002462-20-PLDr August Wolff GmbH & Co KG Arzneimittel160